Craig-Hallum analyst Adam Vogel initiated coverage of Design Therapeutics (DSGN) with a Buy rating and $15 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics upgraded to Outperform from Market Perform at Leerink
- RBC upgrades Design Therapeutics to Outperform into ‘more eventful’ 2026
- Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
- Design Therapeutics Reports Q3 2025 Financial Results
- Design Therapeutics reports Q3 EPS (30c), consensus (34c)